Stay updated on Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA sitewide NIH banner announcing a terminology transition from “Artificial Intelligence” to “Super Intelligence” was removed. The study record continues to display a 403 Forbidden error.SummaryDifference1%

- Check15 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the study page still displays a 403 Forbidden error instead of study details.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide notice announces NIH’s transition to using “Super Intelligence” instead of “Artificial Intelligence.” It appears above the unavailable study record.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the expected content and navigation. This indicates an access issue or site restriction affecting visibility of the study details.SummaryDifference21%

Stay in the know with updates to Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.